Printed From BioPortfolio.com

Massively parallel de novo protein design for targeted therapeutics

23:08 EDT 27 Sep 2017 | Nature Publishing

A massively parallel computational and experimental approach for de novo designing and screening small hyperstable proteins targeting influenza haemagglutinin and botulinum neurotoxin B identifies new therapeutic candidates more robust than traditional antibody therapies.

Original Article: Massively parallel de novo protein design for targeted therapeutics

Give dad the gift of knowledge. Order his DNA Ancestry kit this Father's Day for $99 at 23andMe! Ord

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Swine Flu - H1N1 influenza - H7N9
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of virus). The H1N1 flu virus will be one of the main vi...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

Topics

Massively parallel de novo protein design for targeted therapeutics

More From BioPortfolio on "Massively parallel de novo protein design for targeted therapeutics"

Relevant Topics

News Quicklinks